top of page

Biopharma Daily Updates - 12/22/20

XBI $151.13 (+0.8%) 📈


COVID:


$KNSA (-0.2%) - Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation


$RDHL (+0.1%) - RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue



PIPELINE:

$VYGR (+3%) - Voyager Therapeutics Provides Update On NBIb-1817 (VY-AADC) Gene Therapy Program


$SPPI (-3%) - Spectrum Provides Poziotinib Update after Successful Pre-NDA Meeting with the FDA


$BCRX (-8.5%) - BioCryst Provides Update on Galidesivir Program


$NKTR (+0.4%) - Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million


$OCUL (+5%) - Ocular Therapeutix™ Announces Submission to the FDA of a Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis


$RYTM (-4.5%) - Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes


FINANCIAL:

$RGNX (+6%) - REGENXBIO ANNOUNCES AGREEMENT TO MONETIZE PORTION OF ZOLGENSMA® ROYALTIES FOR $200 MILLION


0 comments

Commentaires


bottom of page